Transactivated EGFR mediates α 1-AR-induced STAT3 activation and cardiac hypertrophy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 5, 2011, Pages

  Li, Yan ^a,b   Zhang, Hui ^a,b   Liao, Wenqiang ^a,b   Song, Yao ^a,b   Ma, Xiaowei ^a,b   Chen, Chao ^a,b   Lu, Zhizhen ^a,b   Li, Zijian ^a,b   Zhang, Youyi ^a,b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

1 adrenergic receptor; Epidermal growth factor receptor; Signal transducers and activators of transcription 3; Transactivation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALPHA 1 ADRENERGIC RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LENTIVIRUS VECTOR; PHENYLEPHRINE; PROPRANOLOL; PROTEIN INHIBITOR; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA TRANSCRIPTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADAM PROTEINS; ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; PHENYLEPHRINE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TYROSINE;

EID: 80355134501     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00338.2011     Document Type: Article

References (47)

1. Barki-Harrington L, Perrino C, Rockman HA. Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc Res 63: 391-402, 2004.
2. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol 10, Suppl 11: S62-S68, 1999.
3. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, Dawn B, Molkentin JD, Sanganalmath SK, Zhu Y, Xuan YT. A murine model of inducible, cardiac-specific deletion of STAT3: Its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 50: 589-597, 2011.
4. Chan HW, Smith NJ, Hannan RD, Thomas WG. Tackling the EGFR in pathological tissue remodelling. Pulm Pharmacol Ther 19: 74-78, 2006.
5. Cipolletta E, Monaco S, Maione AS, Vitiello L, Campiglia P, Pastore L, Franchini C, Novellino E, Limongelli V, Bayer KU, Means AR, Rossi G, Trimarco B, Iaccarino G, Illario M. Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology 151: 2747-2759, 2010.
6. Docherty JR. Subtypes of functional alpha1-adrenoceptor. Cell Mol Life Sci 67: 405-417, 2010.
7. Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ, Rockman HA. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 103: 1453-1458, 2001.
8. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 102: 279-297, 2007.
9. Frias MA, Rebsamen MC, Gerber-Wicht C, Lang U. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovasc Res 73: 57-65, 2007.
10. Guo J, Gertsberg Z, Ozgen N, Steinberg SF. p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 104: 660-669, 2009.
11. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstric-tion through the epidermal growth factor-receptor pathway. Circ Res 94: 68-76, 2004.
12. Herrlich A, Daub H, Knebel A, Herrlich P, Ullrich A, Schultz G, Gudermann T. Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc Natl Acad Sci USA 95: 8985-8990, 1998.
13. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 107: 131-137, 2005.
14. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Muller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 122: 145-155, 2010.
15. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, Fu XY. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100: 12929-12934, 2003.
16. Karkoulias G, Mastrogianni O, Lymperopoulos A, Paris H, Flordellis C. alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFR. Cell Signal 18: 729-739, 2006.
17. Kodama H, Fukuda K, Pan J, Makino S, Baba A, Hori S, Ogawa S. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81: 656- 663, 1997.
18. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104: e9-18, 2009.
19. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Kishimoto T, Yamauchi-Takihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopa-thy. Proc Natl Acad Sci USA 97: 315-319, 2000.
20. Kurdi M, Booz GW. Deciphering STAT3 signaling in the heart: plasticity and vascular inflammation. Congest Heart Fail 16: 234-238, 2010.
21. Lachnit WG, Tran AM, Clarke DE, Ford AP. Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol 120: 819-826, 1997.
22. Le DB, Heery DM, Gaudon C, vom BE, Losson R. Yeast two-hybrid screening for proteins that interact with nuclear hormone receptors. Methods Mol Biol 176: 227-248, 2001.
23. Liao W, Wang S, Han C, Zhang Y. 14-3-3 Proteins regulate glycogen synthase 3beta phosphorylation and inhibit cardiomyocyte hypertrophy. FEBS J 272: 1845-1854, 2005.
24. Maruyama Y, Nishida M, Sugimoto Y, Tanabe S, Turner JH, Kozasa T, Wada T, Nagao T, Kurose H. Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy. Circ Res 91: 961-969, 2002.
25. Mendez M, LaPointe MC. PGE2-induced hypertrophy of cardiac myo-cytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol 288: H2111-H2117, 2005.
26. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-bind-ing epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280: 26592-26599, 2005.
27. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuy-ama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296: H585-H593, 2009.
28. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18: 2344-2354, 2004.
29. Ross SA, Rorabaugh BR, Chalothorn D, Yun J, Gonzalez-Cabrera PJ, McCune DF, Piascik MT, Perez DM. The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model. Cardiovasc Res 60: 598-607, 2003.
30. Saito S, Frank GD, Motley ED, Dempsey PJ, Utsunomiya H, Inagami T, Eguchi S. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transac-tivation. Biochem Biophys Res Commun 294: 1023-1029, 2002.
31. Santiskulvong C, Rozengurt E. Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Exp Cell Res 290: 437-446, 2003.
32. Smith NJ, Chan HW, Osborne JE, Thomas WG, Hannan RD. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci 61: 2695-2703, 2004.
33. Sun Y, McGarrigle D, Huang XY. When a G protein-coupled receptor does not couple to a G protein. Mol Biosyst 3: 849-854, 2007.
34. Szabo-Fresnais N, Lefebvre F, Germain A, Fischmeister R, Pomer-ance M. A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. Cell Signal 22: 1143-1152, 2010.
35. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90: 135-142, 2002.
36. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277: 2028-2032, 2002.
37. Tian ZJ, Cui W, Li YJ, Hao YM, Du J, Liu F, Zhang H, Zu XG, Liu SY, Chen L, An W. Different contributions of STAT3, ERK1/2, and PI3-K signaling to cardiomyocyte hypertrophy by cardiotrophin-1. Acta Pharmacol Sin 25: 1157-1164, 2004.
38. Villalobos-Molina R, Lopez-Guerrero JJ, Ibarra M. Alpha 1D- and alpha 1A-adrenoceptors mediate contraction in rat renal artery. Eur J Pharmacol 322: 225-227, 1997.
39. Waldrop BA, Mastalerz D, Piascik MT, Post GR. Alpha(1B)- and alpha(1D)-Adrenergic receptors exhibit different requirements for agonist and mitogen-activated protein kinase activation to regulate growth responses in rat 1 fibroblasts. J Pharmacol Exp Ther 300: 83-90, 2002.
40. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250, 1995.
41. Willey CD, Palanisamy AP, Johnston RK, Mani SK, Shiraishi H, Tuxworth WJ, Zile MR, Balasubramanian S, Kuppuswamy D. STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci 4: 184-199, 2008.
42. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 18: 443-451, 2008.
43. Yue H, Li W, Desnoyer R, Karnik SS. Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res 85: 90-99, 2010.
44. Zhang H, Feng W, Liao W, Ma X, Han Q, Zhang Y. The gp130/STAT3 signaling pathway mediates beta-adrenergic receptor-induced atrial natriuretic factor expression in cardiomyocytes. FEBS J 275: 3590-3597, 2008.
45. Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, Gach A, Cui L, Liao R, Mende U. Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281: 5811-5820, 2006.
46. Zhou RH, Pesant S, Cohn HI, Eckhart AD. Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation. Life Sci 82: 174-181, 2008.
47. Zou MX, Roy AA, Zhao Q, Kirshenbaum LA, Karmazyn M, Chidiac P. RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes. Cell Signal 18: 1655-1663, 2006.